Legend Biotech (NASDAQ:LEGN – Get Free Report) and Neuphoria Therapeutics (NASDAQ:NEUP – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.
Valuation and Earnings
This table compares Legend Biotech and Neuphoria Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Legend Biotech | $1.03 billion | 3.64 | -$296.80 million | ($0.25) | -77.28 |
| Neuphoria Therapeutics | $1.17 million | 16.23 | -$13.45 million | ($6.22) | -0.56 |
Volatility & Risk
Legend Biotech has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500.
Institutional and Insider Ownership
70.9% of Legend Biotech shares are owned by institutional investors. Comparatively, 15.9% of Neuphoria Therapeutics shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by insiders. Comparatively, 1.5% of Neuphoria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Legend Biotech and Neuphoria Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Legend Biotech | 1 | 5 | 9 | 0 | 2.53 |
| Neuphoria Therapeutics | 1 | 2 | 0 | 0 | 1.67 |
Legend Biotech currently has a consensus target price of $55.79, suggesting a potential upside of 188.75%. Neuphoria Therapeutics has a consensus target price of $7.00, suggesting a potential upside of 99.43%. Given Legend Biotech’s stronger consensus rating and higher probable upside, equities analysts clearly believe Legend Biotech is more favorable than Neuphoria Therapeutics.
Profitability
This table compares Legend Biotech and Neuphoria Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Legend Biotech | -7.21% | -8.71% | -5.40% |
| Neuphoria Therapeutics | N/A | -38.31% | -28.92% |
Summary
Legend Biotech beats Neuphoria Therapeutics on 8 of the 14 factors compared between the two stocks.
About Legend Biotech
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.
About Neuphoria Therapeutics
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.
Receive News & Ratings for Legend Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Legend Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
